Both membranous stain intensity and percentage of tumour cells stained are critical for CLDN18.2 reporting1
In addition to membranous stain intensity and percentage of tumour cells stained, it is recommended that the biomarker report also include:
Integrated reporting:
- The type of testing method used
- A description of the status of the sample, such as “positive,” “negative,” or “inconclusive”
- Any relevant notes or observations regarding the sample or results
How to Report CLDN18.2
Kristina A. Matkowskyj, MD, PhD
CLDN18.2 Reporting Template
Developed collaboratively by the CLDN18.2 Key External Expert Committee, this template can help you generate reporting and integrate CLDN18.2 reporting into your current protocols.
Using the CLDN18.2 Reporting Template
Kristina A. Matkowskyj, MD, PhD
Consistent, integrated reporting of biomarkers can inform clinical decision making and patient care2
Integrated biomarker reporting:
- Gives the HCP the ability to review biomarker test results that inform clinical approach
- Can be used as a tool to help pathologists educate the multidisciplinary team
Stay up to date on CLDN18.2
Do you want more information?
References: 1. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med 2021;11(11):1095. 2. Warner JL, Jain SK, Levy MA. Integrating cancer genomic data into electronic health records. Genome Medicine 2016;8(113).